Hengrui Pharma Secures Breakthrough Therapy Designation for SHR‑1501 in China
CompanyDrug

Hengrui Pharma Secures Breakthrough Therapy Designation for SHR‑1501 in China

GE Healthcare Eyes Sale of China Unit Amid Revenue Decline
Others

GE Healthcare Eyes Sale of China Unit Amid Revenue Decline

Hengrui Pharma Secures NMPA Approval for Two Novel Immune‑Inflammatory Drugs
CompanyDrug

Hengrui Pharma Secures NMPA Approval for Two Novel Immune‑Inflammatory Drugs

GenSci Secures Exclusive Rights to ALK’s House Dust Mite Allergy Therapies in China
CompanyDeals

GenSci Secures Exclusive Rights to ALK’s House Dust Mite Allergy Therapies in China

Jiangsu Hengrui Secures Priority Review for Trastuzumab Rezetecan in HER2‑Positive Breast Cancer
CompanyDrug

Jiangsu Hengrui Secures Priority Review for Trastuzumab Rezetecan in HER2‑Positive Breast Cancer

Chongqing Genrix Secures NMPA Trial Approval for GR2301 IL‑15 Antibody in Vitiligo
CompanyDrug

Chongqing Genrix Secures NMPA Trial Approval for GR2301 IL‑15 Antibody in Vitiligo

Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17‑Positive Solid Tumors
CompanyDrug

Suzhou Zelgen Secures NMPA Approval for ZGGS34 TriTEs Targeting MUC17‑Positive Solid Tumors

Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 Phase 3 Trial
CompanyDrug

Eli Lilly’s Orforglipron Outperforms Oral Semaglutide in ACHIEVE‑3 Phase 3 Trial

Eisai China Partners with DSM‑Firmenich’s i‑Health to Bring Lactéol to Mainland China
CompanyDeals

Eisai China Partners with DSM‑Firmenich’s i‑Health to Bring Lactéol to Mainland China

Biocytogen Eyes A‑Share Listing on Shanghai’s STAR Market to Fund Preclinical R&D Growth
CompanyDeals

Biocytogen Eyes A‑Share Listing on Shanghai’s STAR Market to Fund Preclinical R&D Growth

Jiangsu Hengrui HRS‑5635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis B
CompanyDrug

Jiangsu Hengrui HRS‑5635 Seeks Breakthrough Therapy Designation for Chronic Hepatitis B

Roche Announces $2.4 B Acquisition of 89bio, Targeting Liver and Cardiometabolic Therapies
CompanyDeals

Roche Announces $2.4 B Acquisition of 89bio, Targeting Liver and Cardiometabolic Therapies